Abstract
OBJECTIVE: To evaluate the efficacy of microsurgery on cognitive function, activities of daily living (ADL), and serum biomarkers in patients with glioma. METHODOLOGY: This was a retrospective study. A total of 120 eligible patients with glioma were enrolled from Baoding No.1 Hospital from May 2023 to December 2024 and randomly divided into two groups. The control group underwent conventional craniotomy for tumor resection, while the study group opted for microsurgery. The surgical outcomes were compared between the two groups. Additionally, levels of inflammatory markers (interleukin-6 [IL-6], serum amyloid A [SAA], C-reactive protein [CRP], and tumor necrosis factor-alpha [TNF-α]) and cytokines (arginine vasopressin [AVP], oxytocin [OT], and β-endorphin [β-EP]), cognitive function, and ADL were assessed before and after surgery. RESULTS: The surgical outcomes of study group were significantly superior to control group. After treatment, levels of IL-6, CRP, SAA, and TNF-α were significantly lower in the study group than in the control group, while the levels of AVP, OT, and β-EP were significantly higher in the study group (p = 0.00, respectively). Postoperative cognitive function, including language, memory, and orientation, was significantly better in the study group than in the control group (p = 0.00). At three and six months postoperative, the ADL scores in the study group were higher than in the control group (p = 0.00). CONCLUSION: Microsurgery is an effective, efficient treatment modality for the treatment of glioma, which is worthy of clinical promotion.